Huanjia Zhang

The Seattle-based immune sequencing firm booked $37.6 million in revenues, with 43 percent from immune medicine and 57 percent from its minimal residual disease business.

With a sole focus on the diagnostics market, the company has rolled out dozens of NGS tests for both oncology and genetic diseases.

Developed by Syracuse University researchers, the approach combines specific binders with a common nanopore to detect various types of proteins.

Rolled out in partnership with Fabric Genomics, the test includes clinical WGS and variant analysis and interpretation services with a turnaround time of four weeks.

Reporting 2022 earnings last week, the Chinese genomics firm revealed its new entities on multiple continents as part of its global expansion strategy.

The private payor published new coverage criteria for whole-genome sequencing tests for patients with a variety of non-cancer indications.

The Seattle-based immune sequencing firm reported a 46 percent increase in fourth quarter revenues, about equally split between its MRD and immune medicine businesses.

Through its OEM partner, the company secured NMPA registrations for IVD use in China for its bone marrow aspirate DNA exaction kit and its DNA staining reagents.

Acquired in December 2021, PPD delivered over 20 percent of Thermo Fisher's core organic revenue growth in the fourth quarter and contributed $1.90 billion in revenue.

Releasing Q3 results, the Seattle-based immune system biotechnologies firm set its new full-year revenue guidance to the range of $185 million to $190 million.